US 12,448,440 B2
Compositions comprising antibodies or antibody fragments which bind the P2X4 receptor
Karin Westlund High, Albuquerque, NM (US); Ravi Venkata Durvasula, Albuquerque, NM (US); and Adinarayana Kunamneni, Albuquerque, NM (US)
Assigned to LOYOTA UNIVERSITY OF CHICAGO, Maywood, IL (US); and UNM Rainforest Innovations, Albuquerque, NM (US)
Appl. No. 17/637,350
Filed by UNM Rainforest Innovations, Albuquerque, NM (US); and LOYOLA UNIVERSITY OF CHICAGO, Maywood, IL (US)
PCT Filed Aug. 21, 2020, PCT No. PCT/US2020/047360
§ 371(c)(1), (2) Date Feb. 22, 2022,
PCT Pub. No. WO2021/041194, PCT Pub. Date Mar. 4, 2021.
Claims priority of provisional application 62/890,879, filed on Aug. 23, 2019.
Prior Publication US 2022/0298238 A1, Sep. 22, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 29/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 29/00 (2018.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)] 6 Claims
 
1. A composition comprising:
an antibody or antibody fragment that specifically binds to a P2X family receptor, and a pharmaceutically acceptable carrier,
wherein the P2X family receptor is P2X4, wherein the antibody comprises the CDRs comprising amino acids 28-35, amino acids 56-58, amino acids 102-112, amino acids 177-183, amino acids 201-203 and amino acids 242-247 of SEQ ID NO:1.